TuHURA Biosciences, Inc./NV
| Metric | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Research and development expenses | $20.5M+54.0% | $13.3M+400.8% | $2.7M-71.7% | $9.4M+1.0% | $9.3M |
| Acquisition-related costs (note 5) | $3.7M+735.6% | $440K | — | — | — |
| General and administrative expenses | $7.6M+95.8% | $3.9M-33.1% | $5.8M+39.6% | $4.1M-24.4% | $5.5M |
| Operating Loss | -$31.8M-80.2% | -$17.6M-108.8% | -$8.5M+71.6% | -$29.8M-101.2% | -$14.8M |
| Employee Retention Tax Credit | $114K | — | — | — | — |
| Grant income | $714K+1138.1% | $58K | — | $42K | — |
| Interest expense | -$625K+84.9% | -$4.1M | — | -$19K | — |
| Interest income | $136K-62.3% | $362K | — | $90K | — |
| Change in fair value of derivative liability | -$314K | — | — | — | — |
| Change in fair value of Kineta merger holdback shares | $1.6M | — | — | — | — |
| Loss on Kineta employee separation payments assumed from merger | -$185K | — | — | — | — |
| Total Other Income (Expense) | $1.7M+143.2% | -$4.0M | — | $448K | — |
| Net Loss | -$30.1M-38.6% | -$21.7M-160.6% | -$8.3M+71.6% | -$29.3M-100.1% | -$14.6M |
| Series A Preferred cash dividend | -$8K-300.0% | -$2K+73.9% | -$8K | — | -$8K |
| Deemed dividend on warrant modifications | $0+100.0% | -$965K | — | — | — |
| Net Loss attributable to common stockholders | -$30.1M-32.7% | -$22.6M-166.4% | -$8.5M+71.0% | -$29.3M-95.2% | -$15.0M |
| Net Loss per share, basic | -$0.63+47.9% | -$1.21+99.6% | -$320.00-12855.5% | -$2.47+100.0% | -$9270.00 |
| Net Loss per share, diluted | -$0.63+47.9% | -$1.21 | — | -$2.47 | — |
| Weighted-average shares outstanding, basic | 47.9M+156.8% | 18.7M-99.9% | 26.35B+221546.7% | 11.9M-99.3% | 1.62B |
| Weighted-average shares outstanding, diluted | 47.9M+156.8% | 18.7M | — | 11.9M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.